Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $13.25.

IMRX has been the topic of several research analyst reports. Mizuho boosted their target price on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 18th. Chardan Capital reissued a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Finally, Oppenheimer dropped their target price on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th.

Immuneering Price Performance

Shares of IMRX stock traded down $0.17 during mid-day trading on Wednesday, hitting $4.13. The company had a trading volume of 317,161 shares, compared to its average volume of 2,580,630. Immuneering has a 52-week low of $1.00 and a 52-week high of $4.60. The stock's 50 day moving average price is $2.58 and its 200-day moving average price is $1.98. The company has a market capitalization of $148.64 million, a P/E ratio of -2.11 and a beta of 0.38.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). On average, equities research analysts expect that Immuneering will post -1.86 earnings per share for the current year.

Insider Buying and Selling at Immuneering

In related news, Director Peter Feinberg purchased 25,000 shares of the business's stock in a transaction dated Wednesday, June 18th. The stock was acquired at an average price of $2.53 per share, for a total transaction of $63,250.00. Following the completion of the purchase, the director directly owned 136,766 shares of the company's stock, valued at $346,017.98. This trade represents a 22.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas J. Schall acquired 9,500 shares of the company's stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average cost of $3.66 per share, for a total transaction of $34,770.00. Following the acquisition, the director directly owned 52,885 shares of the company's stock, valued at $193,559.10. This trade represents a 21.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 127,507 shares of company stock worth $334,318. 22.90% of the stock is owned by insiders.

Institutional Trading of Immuneering

Several large investors have recently bought and sold shares of the company. Southport Management L.L.C. boosted its stake in shares of Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock valued at $473,000 after acquiring an additional 10,000 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Immuneering during the fourth quarter valued at $390,000. HighTower Advisors LLC boosted its stake in shares of Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock valued at $128,000 after acquiring an additional 12,600 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Immuneering by 77.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after acquiring an additional 22,400 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after acquiring an additional 10,126 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company's stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.